Loading clinical trials...

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Comparison of the Safety, Tolerability, and Immunogenicity of 3 Consistency Lots of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) in Healthy Children

NCT00985153•Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This study will compare three consistency lots of ProQuad to each other as well as to M-M-R II and Varivax, administered concomitantly at different injection sites, with respect to immunogenicity, safety, and tolerability.

Eligibility

Age

1 - 1 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•In good health
•Negative clinical history of measles, mumps, rubella, varicella, and zoster

Exclusion Criteria

•Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or in combination
•Any immune impairment or deficiency
•Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to vaccination
•Vaccination with an inactive vaccine with in the past 14 days
•Vaccination with a live vaccine within the past 30 days

Key Dates

Start Date

March 1, 2000

Primary Completion Date

May 1, 2001

Completion Date

May 1, 2001

Last Updated

November 23, 2015

Enrollment

3,927

ACTUAL participants

Conditions

MeaslesMumpsRubellaVaricella

Interventions

Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live

BIOLOGICAL

Comparator: Varivax

BIOLOGICAL

Comparator: M-M-R II

BIOLOGICAL

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

NCT07112846

ExanthemaDengue Fever+3 more

View study

COMPLETEDPHASE4

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

NCT03460002

Measles VaccinationOral Polio Vaccine+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 23, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Inclusion Criteria

Exclusion Criteria

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

Co-administration Study of OCV, TCV and MR

Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants